Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo de ustequinumabe em participantes pediátricos com doença de Crohn moderada a gravemente ativa (UNITI Jr)

2 de julho de 2026 atualizado por: Janssen Research & Development, LLC

Um Estudo de Fase 3 da Eficácia, Segurança e Farmacocinética do Ustequinumabe como Tratamento de Indução Intravenosa Aberta Seguido de Manutenção Subcutânea Randomizada Duplo-cego com Ustequinumabe em Participantes Pediátricos com Doença de Crohn Moderadamente a Severamente Ativa

O objetivo deste estudo é avaliar a eficácia da dosagem de ustequinumabe na indução da remissão clínica (Global) e na manutenção da remissão clínica (US); avaliar o perfil de segurança e a exposição ao ustequinumabe (farmacocinética [PK]) em participantes pediátricos com doença de Crohn moderada a gravemente ativa.

Visão geral do estudo

Status

Concluído

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Real)

101

Estágio

  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

      • Aachen, Alemanha, 52074
        • Universitätsklinikum Aachen
      • Berlin, Alemanha, 13353
        • Charite-Universitätsmedizin Berlin - Berlin
      • Essen, Alemanha, 45147
        • Universitätsklinikum Essen
      • Hanover, Alemanha, 30625
        • Medizinische Hochschule Hannover
      • Munich, Alemanha, 80337
        • Dr. von Haunersches Kinderspital
      • Regensburg, Alemanha, 93049
        • KUNO Klinik St. Hedwig
      • Ulm, Alemanha, 89075
        • Universitätsklinikum Ulm
      • Brussels, Bélgica, 1200
        • Cliniques Universitaires Saint Luc
      • Brussels, Bélgica, 1020
        • Universitair Kinderziekenhuis Koningin Fabiola
      • Ghent, Bélgica, 9000
        • UZ Gent
      • Jette, Bélgica, 1090
        • UZ Brussel
      • Leuven, Bélgica, 3000
        • UZ Leuven
    • Delaware
      • Wilmington, Delaware, Estados Unidos, 19803
        • Nemours DuPont Hospital for Children
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30342
        • Children's Center for Digestive Health Care
    • Minnesota
      • Rochester, Minnesota, Estados Unidos, 55905
        • Mayo Clinic
    • New Jersey
      • Morristown, New Jersey, Estados Unidos, 07962
        • Morristown Memorial Hospital
    • North Carolina
      • Charlotte, North Carolina, Estados Unidos, 28207
        • Levine Childrens at Atrium Health
    • Ohio
      • Cleveland, Ohio, Estados Unidos, 44106
        • University Hospitals Cleveland Medical Center
    • Pennsylvania
      • Hershey, Pennsylvania, Estados Unidos, 17033
        • Penn State Hershey Children's Hospital
    • Texas
      • Fort Worth, Texas, Estados Unidos, 76104
        • Cook Childrens Medical Center
    • Virginia
      • Fairfax, Virginia, Estados Unidos, 22031
        • Pediatric Specialists Of Virginia
      • Budapest, Hungria, 1083
        • Semmelweis Egyetem
      • Debrecen, Hungria, 4032
        • Debreceni Egyetem Klinikai Kozpont
      • Miskolc, Hungria, 3526
        • Borsod Abauj Zemplen Varmegyei Kozponti Korhaz es Egyetemi Oktato Korhaz
      • Nyíregyháza, Hungria, 4400
        • Szabolcs Szatmár Bereg Vármegyei Oktatókórház
      • Szeged, Hungria, 6720
        • Szegedi Tudományegyetem, Gyermekgyógyászati Klinika és Gyermekegészségügyi Centrum
      • Be’er Ya‘aqov, Israel, 70300
        • Yitzhak Shamir Medical Center
      • Haifa, Israel, 34362
        • Carmel Medical Center
      • Jerusalem, Israel, 9103102
        • Shaare Zedek Medical Center
      • Petah Tikva, Israel, 4920235
        • Schneider Children's Medical Center
      • Bunkyō City, Japão, 113 8431
        • Juntendo University Hospital
      • Gunma, Japão, 371-0034
        • Gunma University Hospital
      • Ikoma, Japão, 630-0293
        • Kindai University Nara Hospital
      • Kurume, Japão, 830-0011
        • Kurume University Hospital
      • Saitama Shi, Japão, 330-8777
        • Saitama Childrens Medical Center
      • Sendai, Japão, 989-3126
        • Miyagi Children's Hospital
      • Setagaya Ku, Japão, 157 8535
        • National Center for Child Health and Development
      • Shimotsuke, Japão, 329-0498
        • Jichi Medical University Hospital
      • Tsu, Japão, 514 8507
        • Mie University Hospital
      • Gdansk, Polônia, 80 803
        • Szpital im. M. Kopernika
      • Krakow, Polônia, 30 663
        • Uniwersytecki Szpital Dzieciecy w Krakowie
      • Rzeszów, Polônia, 35-302
        • Korczowski Bartosz Gabinet Lekarski
      • Warsaw, Polônia, 04 501
        • WIP Warsaw IBD Point Profesor Kierkus
      • Warsaw, Polônia, 04 730
        • Instytut Pomnik Centrum Zdrowia Dziecka
      • Birmingham, Reino Unido, B4 6NH
        • Birmingham Children's Hospital
      • Bristol, Reino Unido, BS2 8BJ
        • University Hospitals Bristol and Weston NHS Foundation Trust
      • Cambridge, Reino Unido, CB2 0QQ
        • Cambridge University Hospitals NHS Foundation Trust
      • Edinburgh, Reino Unido, EH16 4TJ
        • Royal Hospital for Children and Young People
      • London, Reino Unido, E1 2AT
        • Royal London Hospital
      • Kazan', Rússia, 420138
        • Kazan State Medical University
      • Moscow, Rússia, 119571
        • Russian National Research Medical University named after N.I.Pirogov
      • Nizhny Novgorod, Rússia, 603950
        • Privolzhsky Research Medical University of Ministry of Health of Russian Federation
      • Yaroslavl, Rússia, 150032
        • Yaroslavl Regional Children's Clinical Hospital

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

2 anos a 17 anos (Filho)

Aceita Voluntários Saudáveis

Não

Descrição

Critério de inclusão:

  • Ter doença de Crohn ou doença de Crohn fistulizante com colite ativa, ileíte ou ileocolite, confirmada a qualquer momento no passado por endoscopia e histologia
  • Deve ter doença de Crohn moderada a gravemente ativa (conforme definido por uma pontuação inicial do Índice de Atividade da Doença de Crohn Pediátrica [PCDAI] superior a [>] 30); ter ileocolonoscopia com evidência de doença de Crohn ativa definida como presença de ulceração (que é igual à pontuação endoscópica simples para doença de Crohn [SES-CD] maior ou igual a [>=] 3) durante a triagem para este estudo. O procedimento de ileocolonoscopia deve ocorrer aproximadamente 3 semanas antes da administração da intervenção do estudo na Semana 0 (Período de Indução). Uma ileocolonoscopia por vídeo gravada dentro de 3 meses antes da visita da Semana 0 (Período de Indução) pode ser usada em caso de nova triagem de um participante que fez uma ileocolonoscopia, mas falhou na triagem inicial por outro motivo, caso a caso, após consulta ao patrocinador. Se não for possível avaliar a ulceração devido a estenose ou preparo inadequado do intestino, pelo menos um dos seguintes critérios pode ser aplicado: proteína C reativa (PCR) anormal (> 0,3 miligrama por decilitro [mg/dL] ou 3,0 miligrama por litro [mg/L] na triagem) ou; calprotectina fecal de >= 250 miligramas por quilograma [mg/kg] ou >= 250 microgramas por grama [mcg/g] na triagem
  • Se estiver recebendo nutrição enteral, deve estar em um regime estável por pelo menos 2 semanas antes da semana de indução 0 (Semana I-0)
  • Mulheres com potencial para engravidar devem ter um teste de gravidez de urina altamente sensível negativo na triagem e na Semana I-0 antes da administração da intervenção do estudo

Critério de exclusão:

  • Tem complicações da doença de Crohn, como estenoses ou estenoses sintomáticas, síndrome do intestino curto ou qualquer outra manifestação que possa exigir cirurgia, que possa impedir o uso do PCDAI para avaliar a resposta à terapia ou possivelmente confundir a capacidade de avaliar a efeito do tratamento com ustequinumabe
  • Tem história de infecção granulomatosa latente ou ativa, histoplasmose ou coccidioidomicose, ou teve infecção micobacteriana não tuberculosa antes da triagem
  • Presença ou história de qualquer malignidade, incluindo presença ou história de doença linfoproliferativa, incluindo linfoma, ou sinais e sintomas sugestivos de possível doença linfoproliferativa, como linfadenopatia de tamanho ou localização incomum (por exemplo, linfonodos no triângulo posterior do pescoço, infraclavicular, epitroclear, ou áreas periaórticas) e gamopatia monoclonal de significado indeterminado, ou hepatomegalia ou esplenomegalia clinicamente significativa
  • Tem história de insuficiência hepática ou renal progressiva ou descontrolada moderada ou grave; ou distúrbios cardíacos, vasculares, pulmonares, gastrointestinais, endócrinos, neurológicos, hematológicos, psiquiátricos (incluindo suicídio) ou distúrbios metabólicos significativos
  • Recebeu uma intervenção experimental incluindo qualquer vacina experimental ou usou um dispositivo médico experimental invasivo dentro de 3 meses antes da primeira dose planejada da intervenção do estudo ou está atualmente inscrito em um estudo experimental; o recebimento de uma vacina experimental para a doença de coronavírus 2019 (COVID-19) não é um critério de exclusão automática

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Dobro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Ustequinumabe Intravenoso (IV) Aberto: Período de Indução
Todos os participantes receberão uma única administração IV de ustequinumabe na semana de indução 0 (I-0) com base na área de superfície corporal (BSA) (miligrama por metro quadrado [mg/m^2]) ou dose de indução em níveis de peso (miligrama por quilograma [mg/kg]).
Ustekinumab será administrado por via intravenosa no período de indução e por via subcutânea no período de manutenção.
Experimental: Ustequinumabe Subcutâneo (SC) A Cada 8 Semanas (q8w): Período de Manutenção
Os participantes receberão administração SC de ustequinumabe q8w com base em BSA (mg/m^2) ou dose de indução por peso (mg/kg) nas semanas de manutenção (Semanas M)-0, M-8, M-16, M-24 , M 32 e M-40 e placebo correspondente nas semanas M-12 e M-36 para manter o cego.
Ustekinumab será administrado por via intravenosa no período de indução e por via subcutânea no período de manutenção.
O placebo correspondente será administrado como injeção SC.
Experimental: Ustequinumabe SC a cada 12 semanas (q12s): período de manutenção
Os participantes receberão administração SC de ustequinumabe a cada 12 semanas com base em BSA (mg/m^2) ou dose de indução de acordo com o peso (mg/kg) nas semanas M-0, M-12, M-24, M-36 e placebo correspondente em Semanas M-8, M-16, M-32 e M-40 para manter o cego.
Ustekinumab será administrado por via intravenosa no período de indução e por via subcutânea no período de manutenção.
O placebo correspondente será administrado como injeção SC.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Global Outcome Measure: Percentage of Participants With Clinical Remission at Induction Week 8 (Week I-8)
Prazo: Induction Week 8 (Week I-8)
Clinical remission was defined as a Pediatric Crohn's Disease Activity Index (PCDAI) score <=10. The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency, and general well-being); laboratory scores (3 items: hematocrit [HCT], erythrocyte sedimentation rate [ESR], Albumin); growth scores (2 items: weight and height); physical examination scores (2 items: abdomen and perirectal disease); and extraintestinal manifestations. The category of severity for each index item is assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality. For hematocrit and erythrocyte SR, the maximum score =5. For albumin level, the maximum score = 10. All items were summed to derive the total score. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Induction Week 8 (Week I-8)
US-specific Outcome Measure: Percentage of Participants With Clinical Remission at Maintenance Week 44
Prazo: Maintenance Week 44 (Study Week 52)
Clinical remission was defined as a Pediatric Crohn's Disease Activity Index (PCDAI) score <=10. The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency, and general well-being); laboratory scores (3 items: HCT, ESR, Albumin); growth scores (2 items: weight and height); physical examination scores (2 items: abdomen and perirectal disease); and extraintestinal manifestations. The category of severity for each index item was assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality. For hematocrit and erythrocyte SR, the maximum score= 5. For albumin level, the maximum score= 10. All items were summed to derive the total score. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Prazo: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with TEAEs were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE did not necessarily have a causal relationship with the intervention. TEAEs were defined as AEs occurring at or after the initial administration of the study intervention.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)
Prazo: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with TESAEs was reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE did not necessarily have a causal relationship with the intervention. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; or congenital anomaly. TESAEs were defined as any SAE occurring at or after the initial administration of the study intervention.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With AEs Leading to Discontinuation of Study Intervention
Prazo: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 40 (Study Week 48)
Number of participants with AEs leading to discontinuation of study intervention were reported.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 40 (Study Week 48)
Global and US-specific Outcome Measures: Number of Participants With AEs of Special Interest (AESI)
Prazo: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE did not necessarily have a causal relationship with the intervention. AESI were defined as any newly identified malignancy, or case of active TB, or opportunistic infection occurring after the first administration of study intervention.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology
Prazo: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with abnormalities in clinical laboratory parameters (hematology) were reported. It included hemoglobin (Hb). Grades 0-4 were based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), where Grade 0 was normal, Grade 1 was mild, Grade 2 was moderate, Grade 3 was severe or medically significant but not immediately life-threatening, and Grade 4 was life-threatening consequences. Higher grades showed more severe abnormalities. Only abnormalities where atleast one participant had data are reported. Inc = increased, Dec= decreased.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Abnormalities in Clinical Laboratory Parameters: Chemistry
Prazo: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with abnormalities in clinical laboratory parameters were reported. It included chemistry measures: alanine aminotransferase (ALT), aspartate aminotransferase (AST),blood bilirubin (BB). Grades 0-4 were based on NCI-CTCAE version 5.0, where Grade 0 was Normal, Grade 1 was mild, Grade 2 was moderate, Grade 3 was severe or medically significant but not immediately life-threatening, and Grade 4 was life-threatening consequences. Higher grades showed more severe abnormalities. Only abnormalities where at least one participant had data are reported. Inc = increased, Dec= decreased.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Reactions Temporally Associated With Intravenous (IV) Infusion (Induction Period) and Subcutaneous (SC) Injection-Site Reactions (Maintenance Period)
Prazo: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with reactions temporally associated with intravenous (IV) infusion (Induction Period) and subcutaneous (SC) Injection-Site Reactions (Maintenance Period) were reported.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Serum Ustekinumab Concentrations
Prazo: Induction Period: Week 0 (Pre-infusion), Week I-0 (1-hour post infusion), Week I-3, Week I-6, and Week I-8; Maintenance Period: Week M-4, Week M-8, Week M-12, Week M-16, Week M-24, Week M-32, Week M-36 and Week M-44
Serum ustekinumab concentrations were reported.
Induction Period: Week 0 (Pre-infusion), Week I-0 (1-hour post infusion), Week I-3, Week I-6, and Week I-8; Maintenance Period: Week M-4, Week M-8, Week M-12, Week M-16, Week M-24, Week M-32, Week M-36 and Week M-44

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Global Outcome Measure: Percentage of Participants With Clinical Remission at Induction Week 6 as Assessed by Short Pediatric Crohn's Disease Activity Index (sPCDAI)
Prazo: Induction Week 6 (Week I-6)
Clinical remission was defined as a short Pediatric Crohn's Disease Activity Index (sPCDAI) score <=10. The sPCDAI was composed of six components: abdominal pain, stool frequency, patient general well-being, body weight, abdominal examination (abdominal mass and tenderness), and extraintestinal manifestations. Each component was assigned a score of 0, 5, 10, or 20, depending on the severity of findings, with higher scores indicating greater disease activity, while lower scores (closer to 0) reflected clinical remission or minimal disease activity. Individual component scores were summed to derive the total sPCDAI score, which ranged from 0 to 90. Higher score indicate greater severity. The sPCDAI score was calculated only when >=3 of the 6 components were available.
Induction Week 6 (Week I-6)
Global Outcome Measure: Percentage of Participants With Clinical Response at Induction Week 8
Prazo: Induction Week 8
Assessment of response in children with Crohn's disease was evaluated using the PCDAI. Clinical response was defined as a reduction from baseline of >=12.5 points in the PCDAI score, calculated by summing weighted scores from 11 items across five domains: symptom history (abdominal pain, stool frequency, and general well-being); laboratory scores (hematocrit, erythrocyte sedimentation rate, and albumin); growth scores (weight and height); physical examination scores (abdominal and perirectal disease); and extraintestinal manifestations. Each index item was assigned a severity score of 0 (normal), 5 (mild abnormality), or 10 (severe abnormality). For HCT and ESR, maximum score was 5, and for albumin level, maximum score was 10. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity. Lower PCDAI scores reflected lower disease activity, with a resulting score of <=30 on the 0-100 scale.
Induction Week 8
Global and US-specific Outcome Measures: Percentage of Participants With Clinical Response at Induction Week 6 as Assessed by sPCDAI
Prazo: Induction Week 6
sPCDAI clinical response was defined as reduction from baseline in the sPCDAI score of >=10. The 6-item sPCDAI score ranges from 0 (no disease activity) to 90 (severe disease activity),calculated by summing weighted scores for abdominal pain, stool frequency, general well-being, body weight, abdominal exam, and extraintestinal manifestations. Each component was assigned a score of 0, 5, 10, or 20, depending on the severity of findings, with higher scores indicating greater disease activity, while lower scores (closer to 0) reflected minimal disease activity. Individual component scores were summed to derive the total sPCDAI score, which ranged from 0 to 90. Higher score indicate greater severity. The sPCDAI score was only calculated when >=3 of the 6 components were available.
Induction Week 6
Global Outcome Measure: Percentage of Participants With Endoscopic Response at Maintenance Week 8 as Assessed by Simplified Endoscopic Score-Crohn's Disease (SES-CD)
Prazo: Maintenance Period Week 8 (Study Week 16)
Endoscopic response was assessed using the Simplified Endoscopic Activity Score for Crohn's Disease (SES-CD), a validated endoscopic scoring system based on four components: size of ulcers, extent of ulcerated surface, extent of affected surface, and presence of narrowing. Each component was scored from 0 to 3 across five intestinal sections: ileum, right colon, transverse colon, left (descending and sigmoid) colon, and rectum. Component scores were summed across all sections to derive a total SES-CD score ranging from 0 to 56, with higher scores indicating greater endoscopic disease severity. Endoscopic response was defined as a >=50% reduction from baseline in SES-CD score or achievement of an SES-CD score <=2 in participants with a baseline SES-CD score >=3.
Maintenance Period Week 8 (Study Week 16)
Global Outcome Measure: Percentage of Participants With Clinical Response at Maintenance Week 8
Prazo: Maintenance Week 8 (Study Week 16)
Clinical response was defined as a reduction from baseline of >=12.5 points in PCDAI score, calculated by summing weighted scores from 11 items across five domains: symptom history(abdominal pain, stool frequency, and general well-being); laboratory scores (hematocrit, erythrocyte sedimentation rate, and albumin); growth scores(weight and height); physical examination scores(abdominal and perirectal disease); extraintestinal manifestations. Each index item was assigned a severity score of 0(normal), 5(mild abnormality), or 10(severe abnormality). For HCT and ESR, maximum score was 5, for albumin level, maximum score was 10. Total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity. Lower PCDAI scores reflected lower disease activity, with resulting score of <=30 on 0-100 scale.
Maintenance Week 8 (Study Week 16)
Global and US-specific Outcome Measures: Percentage of Participants With Endoscopic Response at Maintenance Week 44 as Assessed by SES-CD
Prazo: Maintenance Week 44 (Study Week 52)
Endoscopic response was assessed using the Simplified Endoscopic Activity Score for Crohn's Disease (SES-CD), a validated endoscopic scoring system based on four components: size of ulcers, extent of ulcerated surface, extent of affected surface, and presence of narrowing. Each component was scored from 0 to 3 across five intestinal sections: ileum, right colon, transverse colon, left (descending and sigmoid) colon, and rectum. Component scores were summed across all sections to derive a total SES-CD score ranging from 0 to 56, with higher scores indicating greater endoscopic disease severity. Endoscopic response was defined as a >=50% reduction from baseline in SES-CD score or achievement of an SES-CD score <=2 in participants with a baseline SES-CD score >=3.
Maintenance Week 44 (Study Week 52)
US-specific Outcome Measure: Percentage of Participants With Clinical Response at Maintenance Week 44
Prazo: Maintenance Week 44 (Study Week 52)
Clinical response was defined as a reduction from baseline of >=12.5 points in PCDAI score, calculated by summing weighted scores from 11 items across five domains: symptom history(abdominal pain, stool frequency, and general well-being); laboratory scores (hematocrit, erythrocyte sedimentation rate, and albumin); growth scores(weight and height); physical examination scores(abdominal and perirectal disease); extraintestinal manifestations. Each index item was assigned a severity score of 0(normal), 5(mild abnormality), or 10(severe abnormality). For HCT and ESR, maximum score was 5, for albumin level, maximum score was 10. Total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity. Lower PCDAI scores reflected lower disease activity, with resulting score of <=30 on 0-100 scale.
Maintenance Week 44 (Study Week 52)
US-specific Outcome Measure: Percentage of Participants With Corticosteroid-free Clinical Remission at Maintenance Week 44
Prazo: Maintenance Period Week 44 (Study Week 52)
Corticosteroid-free remission was defined as PCDAI score of <=10 points and not receiving corticosteroids for at least 90 days prior to Week M-44. The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency; and general well-being); laboratory scores (3 items: HCT, ESR, Albumin); growth scores (2 items: weight and height), physical examination scores (2 items: abdomen and perirectal disease), and extraintestinal manifestations. The category of severity for each index item was assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality. For hematocrit and erythrocyte SR, the maximum score= 5. For albumin level, the maximum score= 10. All items were summed to derive the total score. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Maintenance Period Week 44 (Study Week 52)
Global Outcome Measure: Percentage of Participants With Clinical Remission at Maintenance Week 44 Who Had Clinical Remission at Induction Week 8
Prazo: Maintenance Week 44 (Study Week 52)
Clinical remission was defined as Pediatric Crohn's Disease Activity Index (PCDAI) score <=10. The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency; and general well-being); laboratory scores (3 items: HCT, ESR, Albumin); growth scores (2 items: weight and height), physical examination scores (2 items: abdomen and perirectal disease), and extraintestinal manifestations. The category of severity for each index item was assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality. For hematocrit and erythrocyte SR, the maximum score= 5. For albumin level, the maximum score= 10. All items were summed to derive the total score. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Maintenance Week 44 (Study Week 52)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Diretor de estudo: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

6 de abril de 2021

Conclusão Primária (Real)

28 de novembro de 2024

Conclusão do estudo (Real)

3 de março de 2025

Datas de inscrição no estudo

Enviado pela primeira vez

14 de dezembro de 2020

Enviado pela primeira vez que atendeu aos critérios de CQ

14 de dezembro de 2020

Primeira postagem (Real)

17 de dezembro de 2020

Atualizações de registro de estudo

Última Atualização Postada (Real)

30 de julho de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

2 de julho de 2026

Última verificação

1 de julho de 2026

Mais Informações

Termos relacionados a este estudo

Palavras-chave

Outros números de identificação do estudo

  • CR108864
  • 2019-004225-24 (Número EudraCT)
  • CNTO1275CRD3004 (Outro identificador: Janssen Research & Development, LLC)
  • 2023-504978-38-00 (Identificador de registro: EUCT number)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

A política de compartilhamento de dados da Janssen Pharmaceutical Companies of Johnson & Johnson está disponível em www.janssen.com/clinical-trials/transparency. Conforme observado neste site, as solicitações de acesso aos dados do estudo podem ser enviadas por meio do site do Projeto Yale Open Data Access (YODA) em yoda.yale.edu

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .